Page 219 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

DS1-3 vs DS4-5
I-PET1 38 (62.3) 1.22 (0.46-3.20)
I-PET2 442 (41.4) 1.71 (1.32-2.22)
I-PET3 14 (21.9) 2.94 (1.08-7.96)
I-PET4 102 (21.2) 2.95 (1.98-4.40)
DS1-4 vs DS5
∆SUVmax
15 (37.5) 137 (12.7) 9 (15.3) 36 (10.2)
Optimal timing and response criteria of Interim-PET in DLBCL
Table 1. Percentage of PET-positive scans and HRs of I-PET using DS4-5 or DS5 or ∆SUVmax to assign a PET-positive result with 2-year PFS as outcome.
Timing I-PET HR (95% CI) I-PET HR (95% CI) I-PET HR (95% CI) positive positive positive
12 (19.7) 60 (5.6) 4 (6.3) 24 (5)
2.33 (0.88-6.13) 4.91 (3.46-6.97) 4.67 (1.52-14.37) 6.20 (3.62-10.61)
1.46 (0.45-4.80) 2.93 (2.18-3.93) 2.27 (0.73-7.04) 4.65 (2.76-7.83)
Data are presented as n (%), unless otherwise labeled.
Figure 3. Two-year PFS Cox regression stratified for DS4-5 I-PET-positive patients and timing.
Corrected for low-risk (A), low-intermediate risk (B), high-intermediate risk (C), and high-risk (D) IPI groups.
217
8